INCHEON, South Korea , Nov. 19, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced a series of manufacturing deals with a Europe -based pharmaceutical company.
The disclosed deals, worth over USD 66 8 million combined, will run through December 2031 . The latest agreements bring up the company's cumulative contract value for this year to more than USD 4 billion . "We are delighted to expand our partnership with the European pharmaceutical company toward our shared commitment to delivering high-quality biopharmaceuticals to patients, " said John Rim , President and CEO of Samsung Biologics.
" As we further expand strategic collaboration with clients worldwide, we also make continued investments in our capabilities and manufacturing technologies. Our goal is to provide the highest-quality services at every stage and deepen our trusted partnerships ." The company has proactively addressed the evolving needs of clients with a series of significant deals this year , solidifying its customer base across the U.
S., Asia , and Europe . Samsung Biologics has now partnered with 17 of the world' s top 20 pharmaceutical companies and continues to extend contracts with existing clients to support them in advancing innovative therapies.
Samsung Biologics is set to add antibody-drug conjugate (ADC) services to its portfolio, with a dedicated facility to be completed by the end of this year. The company.
